|
|
 | | | |
- close
- close
- close
- close
SPDR S&P Pharmaceuticals ETF (XPH) |
QUOTE AND NEWS
Forbes
Apr 14
Comment
Today, Citigroup (C) raised its price target on shares of Endo Pharmaceuticals Inc. (ENDP) from $42 to $48. With the price adjustment, Citi maintained its buy rating on the Chadds Ford, Pennsylvania based company. Citi’s price adjustment...
Wall Street Sector Selector
Mar 8
Comment
About a month ago I told you about some of my favorite sectors for income right now, and healthcare was one of them. Today I want to drill down a little further and talk about a specific(...)Read the rest of Bargains Abound In Big Pharma-Focused...
Benzinga
Oct 12
Comment
iPath Dow Jones-AIG Sugar Total Return Sub-Index ETN (NYSE: SGG) gained 3.84% on Tuesday, as sugar futures jumped above $27.50. SGG had a volume of 149K traded shares.
PowerShares DB Agriculture Double Long ETN (NYSE: DAG) jumped 3.52%, as...
Wall Street Sector Selector
Oct 12
Comment
In midday trading Tuesday, the SPDR S&P Pharmaceuticals ETF (AMEX:XPH) is outperforming other ETFs, up about 2.71% on the day. Also up on the day are the (...)Read the rest of Tuesday, October 12th ETF Movers: (XPH, EGPT, DBA, VXX, SCJ, DFJ)...
Penny Stock DD
Sep 20
Comment
[wikichart align="right" ticker="TWGP" showannotations="true" livequote="true" startdate="19-03-2010" enddate="19-09-2010" width="300" height="245"]
TowerGroup Inc. (Nasdaq: TWGP) announced it has priced $135 million in convertible senior...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
This article describes an exchange traded fund that tracks an index, commodity, currency, or varied basket of securites. View articles referencing this fund. |
TOP CONTRIBUTORS
SPDR S&P Pharmaceuticals ETF (XPH)
Overview
The SPDR® S&P® Pharmaceuticals ETF seeks to replicate as closely as possible, before expenses, the total return performance of the S&P Pharmaceuticals Select Industry® Index (ticker: SPSIPHTR).
[1]
Fund Information
- Fund Manager - State Street Global Markets, LLC
- Inception Date - 06/19/2006
- Exchange – NYSE Arca
- Index Ticker – XPH
- Intra-day NAV Ticker – XPH.IV
- Expense Ratio - 0.36%
Top Holdings
| Name | Weight | Total Mkt Cap M | Shares Held |
| Johnson & Johnson | 4.33% | 177,272 | 38,311 |
| Pfizer Inc | 4.45% | 143,315 | 142,446 |
| Merck & Co Inc New | 4.55% | 111,030 | 71,136 |
| Abbott Labs | 4.63% | 82,348 | 49,429 |
| Bristol Myers Squibb Co | 4.55% | 49,326 | 103,800 |
| Lilly Eli & Co | 4.53% | 41,951 | 70,529 |
| Allergan Inc | 4.24% | 17,838 | 41,049 |
| Forest Labs Inc | 4.34% | 9,343 | 79,572 |
| Mylan Inc | 4.88% | 5,543 | 152,688 |
| Watson Pharmaceuticals Inc | 4.22% | 4,009 | 63,540 |
Holdings as of 12/08/2009
Other Pharma & Healthcare ETFs
| ETF Name | Fund Manager | Expense Ratio |
| iShares Dow Jones U.S. Pharmaceuticals Index Fund (IHE) | ishares | 0.48% |
| Powershares Dynamic Pharmaceuticals Portfolio ETF (PJP) | Invesco PowerShares | 0.60% |
References
| |||||||
